Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04881318

Compression Garments in the Community With POTS

Compression Garments are a commonly prescribed treatment in Postural Orthostatic Tachycardia Syndrome (POTS). The effectiveness of a proof-of-concept compression garment has been demonstrated in an acute laboratory setting. It is not known if commercially available compression garments that participants wear in their every day lives are effective at improving heart rate and reducing symptoms in POTS. This trial will evaluate the use of commercially available waist-high and abdominal compression garments in adults diagnosed with POTS in a community setting.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Calgary

Calgary, Alberta, T2N 4Z6, Canada

Location status: Recruiting

Location contact

Kate Bourne

CONTACT

403-210-7401

Satish R. Raj, MD MSCI

PRINCIPAL_INVESTIGATOR

About this study

Current treatment of Postural Orthostatic Tachycardia Syndrome (POTS) involves pharmacological and non-pharmacological intervention including salt and fluid loading, exercise, physical countermanuevers, and compression garments. Lower extremity compression garments provide mechanical external pressure to the blood vessels in the legs, thighs and abdomen, shifting blood back to the central circulation to increase preload and stroke volume. With increased stroke volume, cardiac output is maintained without excessive tachycardia. Compression garments are commonly prescribed as a non-pharmacological treatment in POTS, but previously little evidence validated their use. A recent proof-of-concept compression garment study performed by our research lab demonstrated significant HR and symptom reductions with compression, with adult POTS patients in an acute laboratory setting. The effectiveness of commercially available compression garments in a community setting in POTS patients is not known.

In this study, the researchers will use commercially or medically (by prescription) available waist-high compression garments (WHC) that POTS patients use in their daily life, to evaluate compression as a viable long-term treatment option. Additionally, the researchers will perform an optional sub-study of abdominal compression garments (AC), evaluating their effectiveness. Results from this study will be used to inform the practicality and effectiveness of compression garments in the community setting. These findings could rapidly translate to the clinical setting and improve patient care.

Primary Hypothesis: Body compression with commercially available WHC will acutely reduce orthostatic tachycardia, when compared to no compression, in a community setting.

Sub-Study Hypothesis: Body compression with commercially available AC will acutely reduce orthostatic tachycardia, when compared to no compression, in a community setting.

The participant will complete the study in a community setting. The participant will be provided with the study supplies including a Holter monitor to wear during the study. The duration of the study will be up to 4 days in total. The "With Medications" phase is 2 days and the "Without Medications" phase is 2 days. The first randomization is whether to do the WHC studies first after medications have been held for at least 24h or without holding the medications. If the participant will be in the AC Sub-Studies, then they will do those studies during the same window of holding medications (or not) as the WHC study. The second randomization would determine the order of WHC-AC vs. AC-WHC during each window

For each study day, there will be a total of 4 standing tests. Participants will first put on the Holter monitor at the beginning of the study day. The first standing test (OVS #1) will be performed 30 minutes after the participant takes their medications but before putting on the compression garment. The participant will then put on the compression garment. The second (OVS #2) standing test will be performed 30 minutes after putting on the compression garment. The third (OVS #3) standing test will be performed a minimum of 3 hours after putting on the compression garment. After a minimum of 3hours, the participant will then remove the compression garment. The fourth standing test (OVS #4) will be performed 30 minutes after removing the garment. Participants will record their symptoms after each standing test, as well as medications taken each day in the provided study booklet.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Physician diagnosis of Postural Tachycardia Syndrome (POTS)
  • Resident of Canada
  • Owns waist-high compression garment: medical grade or commercially available tights with a pressure rating provided (e.g. 15-18 mmHg, 20-30 mmHg, 30-40 mmHg)
  • Optional Sub-Study: owns an abdominal compression garment (e.g. abdominal shapewear, waist high shorts)
  • Able to participate in a 4-day study (2x2 day segments with a 5-day washout period)

Exclusion criteria

  • Overt cause for postural tachycardia (i.e., acute dehydration, thyroid disease) that precludes POTS diagnosis
  • Not a resident of Canada
  • Participants with somatization or severe anxiety symptoms will be excluded
  • Pregnant (self-reported)
  • Inability to tolerate compression garments for the duration of the study
  • Does not own a waist-high compression garment
  • Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies

Treatment and study plan

Waist-High Compression Tights

Other

Waist-high compression tights providing 15-40 mmHg of pressure.

Other names: Full Length Compression Tights

Abdominal Compression Garments

Other

Abdominal compression garment compressing the abdomen, buttocks, and upper thighs.

Other names: Abdominal shapewear, compression shorts

Medications that modulate heart rate and blood pressure

Drug

Medications that modulate heart rate and blood pressure that participants regularly take. These medications include beta-blockers, midodrine, ivabradine and stimulants.

Primary outcomes

  1. WHC Heart Rate

    Time frame: 10 minutes

    The primary outcome is the delta HR (standing HR - supine HR) in orthostatic vital signs (OVS) #1 (prior to the WHC) and OVS #2 (30min after WHC is applied), in the "Without Medication" phase.

  2. AC Heart Rate

    Time frame: 10 minutes

    The primary outcome is the delta HR (standing HR - supine HR) in orthostatic vital signs (OVS) #1 (prior to the AC) and OVS #2 (30min after AC is applied), in the "Without Medication" phase.

Secondary outcomes

  1. Heart Rate - End of Study Day (WHC)

    Time frame: 10 minutes

    Delta HR measurement from OVS #3 (with WHC) compared to the delta HR from the OVS #4 (without WHC).

  2. Heart Rate - WHC and Medication

    Time frame: 10 minutes

    The delta HR from OVS #1 - OVS #2 in the "With Medication" phase, compared to the delta HR from OVS #1 - OVS #2 in the "Without Medication" phase .

  3. Heart Rate - WHC and AC

    Time frame: 10 minutes

    Delta HR from OVS #1 - OVS #2 on the WHC day, compared to OVS #1 - OVS #2 on the AC day, in the "With Medication" phase. This will provide an assessment of the differential efficacy of commercial WHC versus commercial AC in a home setting.

  4. Heart Rate - End of Study Day (AC)

    Time frame: 10 minutes

    Delta HR measurement from OVS #3 (with AC) compared to the delta HR from the OVS #4 (without AC). This will provide an assessment of the efficacy of commercial AC with prolonged use during the day.

  5. Heart Rate - AC and Medication

    Time frame: 10 minutes

    The delta HR from OVS #1 - OVS #2 in the "With Medication" phase, compared to the delta HR from OVS #1 - OVS #2 in the "Without Medication" phase. This will provide an assessment of the differential efficacy of commercial AC with and without POTS medications.

Study contacts

Contact information is provided by the study sponsor or research team.

Kate M Bourne, BSc

CONTACT

[email protected]

403-210-7401

Sponsors and collaborators

Lead sponsor

University of Calgary

Other

Registry information

Acronym: COM-COM-POTS

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
May 11, 2021
Registry last updated
May 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.